Sex differences in efficacy and toxicity of systemic treatments are an undervalued issue in the era of precision oncology1
Gender medicine aims to improve the treatment of women as well as men. During the workshop, this concept, initially developed by cardiologists such as Marianne Legato and Vera Regitz-Zagrosek, will be presented together with examples of sex differences in disease biology and treatment outcomes from various fields of oncology. The theoretical aspects, for example of disease biology and pharmacology, will be reviewed and their implications for the field of oncology will be discussed with a multidisciplinary faculty and audience.
- To summarise the differences in chromosomes, hormones, metabolism and the immune system between men and women.
- To present differences in body composition between men and women, their impact on drug metabolism and differences in the pharmacology of different classes of anti-cancer drugs, as well as possible strategies for dose individualisation.
- To present differences in disease biology and treatment outcomes in selected types of non sex-related cancers: lymphoma, gastrointestinal cancers and melanoma as examples.
- To describe how current design and reporting of clinical trials in oncology address a potential impact of the sex of patients on all types of outcomes, as well as methodological hurdles in evaluating the impact of gender in clinical trials.
- To discuss the consequences of all the above on research and practice in oncology with faculty and audience and elaborate a workshop report and consensus.
View the final programme
Application for the workshop are now closed.
Dorothea Wagner, Lausanne
B. Özdemir, Lausanne
G-P Dotto, Lausanne
Centre Hospitalier Universitaire Vaudois (CHUV),
Rue du Bugnon 46,
1. Özdemir BC et al. Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the Era of Precision Oncology. J Clin Oncol. 2018 Jul 13:JCO2018783290. doi: 10.1200/JCO.2018.78.3290